Last updated: February 19, 2026
This analysis examines European Patent EP3086783, titled "Compositions comprising novel protein for treating cancer," focusing on its claimed scope, patent family, and the competitive landscape. The patent, filed by Genentech, Inc., covers specific antibody compositions for treating B-cell malignancies, notably Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL).
What Is the Core Invention Claimed in EP3086783?
The central invention described in EP3086783 pertains to novel protein compositions, specifically antibodies, and their use in treating certain hematological cancers. The patent's claims define these compositions by specific amino acid sequences and their binding properties to particular cellular targets.
What are the Key Target Indications?
The patent explicitly identifies its therapeutic focus on B-cell malignancies.
- Chronic Lymphocytic Leukemia (CLL): A slow-growing cancer of the blood and bone marrow.
- Small Lymphocytic Lymphoma (SLL): A type of non-Hodgkin lymphoma closely related to CLL, affecting lymphocytes.
- The patent states that these compositions are effective in treating patients with these conditions.
What are the Specific Antibody Targets?
The claimed antibodies are designed to target specific antigens expressed on the surface of malignant B-cells.
- CD20: This is a transmembrane protein found on B-lymphocytes. The patent claims antibodies that bind to CD20.
- CD38: This is a cell surface protein expressed on lymphocytes and other cells. The patent claims antibodies that bind to CD38.
- The patent asserts that the novel protein compositions exhibit enhanced binding affinity or specific functional properties towards these targets, contributing to their therapeutic efficacy.
What are the Defined Compositions?
EP3086783 defines specific antibody molecules and their formulations.
- Antibody Sequences: The patent includes claims that define antibodies by their specific amino acid sequences, detailing variable heavy (VH) and variable light (VL) chain sequences. This precise definition aims to limit the scope to molecules with the exact specified sequences.
- Antibody Conjugates: The patent covers antibody-drug conjugates (ADCs) and antibody-payload conjugates where the antibody is linked to a cytotoxic agent or another functional payload. These conjugates are designed to deliver a therapeutic agent directly to cancer cells expressing the target antigen.
- Formulations: Claims also encompass pharmaceutical compositions containing the defined antibodies, including excipients and buffers, for administration to patients.
What is the Claimed Scope and Exclusivity?
The exclusivity granted by EP3086783 is determined by the precise wording of its claims. These claims dictate which products and processes are covered by the patent.
What are the Broadest Claims?
While specific claims are detailed, broader claims often capture the general concept.
- Independent Claims: These claims are not dependent on any other claims and define the core invention in its broadest terms. For EP3086783, these typically involve an antibody or antibody fragment that binds to a specific target (e.g., CD20 or CD38) and possesses defined properties or sequence characteristics.
- Dependent Claims: These claims narrow the scope of independent claims by adding specific limitations. For example, a dependent claim might specify particular amino acid sequences for the antibody's variable regions, define specific linker chemistries for ADCs, or enumerate particular pharmaceutical excipients.
How Do Specific Sequence Claims Restrict the Scope?
The inclusion of specific amino acid sequences in claims significantly narrows the patent's reach.
- Sequence Identity: Claims referencing exact amino acid sequences of VH and VL regions provide a high degree of specificity. Competitors would need to design antibodies with different sequences to avoid infringement.
- Percentage Homology: Some claims might refer to antibodies with a certain percentage of sequence homology to the exemplified sequences. This could provide a slightly broader scope, covering antibodies that are substantially similar but not identical.
- Binding Epitopes: Claims may define antibodies by the specific epitope they bind to on the target antigen. This offers protection even if antibody sequences differ, as long as they bind to the same critical region.
What are the Limitations of the Claims?
The patent’s claims are subject to interpretation and potential limitations.
- Prior Art: The scope can be limited by prior art that predates the patent filing date and discloses similar inventions.
- Inventive Step: The claims must be demonstrably inventive over existing knowledge. If aspects of the claimed invention were obvious to a person skilled in the art, they may not be patentable.
- Sufficiency of Disclosure: The patent must enable a person skilled in the art to carry out the invention. If the disclosure is insufficient, claims may be deemed invalid.
What is the Patent Family and Geographic Coverage?
Understanding the patent family and its territorial coverage is crucial for assessing the global reach of the exclusivity granted by EP3086783.
What Countries/Regions Does EP3086783 Cover?
As a European Patent, EP3086783 is initially granted for the European Patent Convention (EPC) member states.
- Validation: Following grant by the European Patent Office (EPO), the patent must be validated in individual EPC member states for it to have legal effect in those countries.
- Key Jurisdictions: Likely validated in major European markets such as Germany, France, the United Kingdom, Spain, Italy, and Switzerland, among others. The exact list of validated countries can be found in patent databases.
What is the Filing and Priority Date?
These dates are critical for determining the patent's term and its relevance against competing technologies.
- Filing Date: December 16, 2015.
- Priority Date: December 24, 2014 (based on an earlier application, likely a US provisional). This date is used to assess novelty and inventiveness against prior art.
What is the Expected Expiry Date?
European patents generally have a term of 20 years from the filing date.
- Expiry: Approximately December 16, 2035.
- Potential Extensions: For pharmaceutical patents, Supplementary Protection Certificates (SPCs) can extend market exclusivity in individual countries beyond the patent expiry date, up to a maximum of 5 years. This extension is calculated based on the time from the first marketing authorization in the relevant territory.
What is the Competitive Landscape for EP3086783?
The competitive landscape is defined by other patents, approved drugs, and ongoing clinical trials that target similar indications or utilize comparable therapeutic modalities.
Who are the Key Competitors and Their Patents?
Several companies are active in developing CD20- and CD38-targeted therapies.
- Genentech (Roche): As the assignee of EP3086783, Genentech is a primary player. They have other relevant patents covering their approved drugs like Rituxan (rituximab), Gazyva (obinutuzumab), and potentially newer generations of antibodies or ADCs.
- Seattle Genetics (Seagen/Pfizer): Holds patents related to ADCs, including those targeting CD20 (e.g., polatuzumab vedotin, Tivdak).
- Janssen (Johnson & Johnson): Has significant patents in the CD38 space, particularly for daratumumab (Darzalex).
- Bayer: Active in B-cell malignancy research, potentially holding patents on other antibody targets or novel delivery mechanisms.
- Amgen: Owns patents related to bispecific antibodies and other novel immunotherapies.
What are the Existing and Emerging Therapies in the Target Indications?
The therapeutic areas of CLL and SLL are well-established, with a range of approved treatments.
- Anti-CD20 Monoclonal Antibodies:
- Rituximab (Rituxan): A first-generation anti-CD20 antibody.
- Ofatumumab (Arzerra): Another anti-CD20 antibody.
- Obinutuzumab (Gazyva): A Type II anti-CD20 antibody with enhanced binding and effector functions, often used in combination therapies.
- Anti-CD38 Monoclonal Antibodies:
- Daratumumab (Darzalex): A highly successful anti-CD38 antibody, primarily for multiple myeloma but also explored in other CD38-expressing hematological malignancies.
- Antibody-Drug Conjugates (ADCs):
- Polatuzumab Vedotin (Polivy): An anti-CD79b ADC approved for diffuse large B-cell lymphoma (DLBCL), illustrating the trend towards targeted payloads. Patents covering similar ADCs targeting CD20 or other B-cell antigens are critical.
- Bispecific Antibodies:
- Epcoritamab (Epkinly): A bispecific T-cell engager targeting CD20 and CD3, approved for DLBCL. Patents in this area are highly competitive.
How Does EP3086783 Intersect with Competitor Patents?
The intersection of EP3086783 with competitor patents defines potential areas of infringement or freedom-to-operate challenges.
- Overlapping Targets: Competitors developing anti-CD20 or anti-CD38 agents will need to carefully navigate the claims of EP3086783. If a competitor's antibody shares key sequence characteristics or binds to the same defined epitope, infringement is possible.
- ADC Technologies: For ADCs, EP3086783's claims related to antibody-payload conjugates could be relevant. Competitors using similar antibody backbones or linker technologies need to assess their alignment with the patent's scope.
- Formulation and Manufacturing: Claims covering specific formulations or manufacturing processes, if present and robust, could also create overlap.
What is the Significance of Patent Litigation and Licensing in This Space?
The high value of oncology therapeutics makes patent litigation and licensing a common feature.
- Infringement Suits: Companies may initiate litigation to enforce their patents against alleged infringers, seeking injunctions and damages.
- Validity Challenges: Competitors may challenge the validity of patents, arguing they are anticipated by prior art or lack an inventive step.
- Licensing Agreements: Companies may enter into licensing agreements to access patented technologies, enabling them to develop or commercialize their own products. This is common for antibody frameworks or specific payload technologies.
- Freedom-to-Operate (FTO) Assessments: Robust FTO analyses are essential for R&D and commercialization decisions to identify and mitigate patent infringement risks.
Key Takeaways
European Patent EP3086783, held by Genentech, Inc., provides exclusivity for novel antibody compositions targeting CD20 and CD38 for the treatment of CLL and SLL. The patent's scope is defined by specific amino acid sequences for antibodies and claims encompassing antibody-drug conjugates. Its geographic coverage extends to validated EPC member states, with an anticipated expiry around December 2035, potentially extended by SPCs. The competitive landscape is crowded with existing and emerging CD20/CD38-targeted therapies, necessitating careful navigation of overlapping patents and technologies.
Frequently Asked Questions
-
Does EP3086783 claim antibodies with specific binding affinities?
While the patent defines antibodies by their sequences and target binding, specific quantitative binding affinity values (e.g., dissociation constants) may be detailed in the patent's description and exemplified in specific claims or embodiments rather than being a universally defining aspect of all claims.
-
Can competitors develop bispecific antibodies targeting CD20 or CD38 without infringing EP3086783?
The ability to develop bispecific antibodies without infringement depends on the precise wording of EP3086783's claims. If the claims define antibodies by their individual component sequences (e.g., VH/VL of one arm) or by specific binding characteristics that are incorporated into a bispecific format, infringement could occur. Claims specifically directed to bispecific formats would be more directly relevant.
-
What is the impact of potential SPCs on the market exclusivity of EP3086783?
Supplementary Protection Certificates (SPCs) can extend the market exclusivity for a patented medicinal product in individual European countries for up to five years beyond the patent's expiry date. This extension is crucial for recouping R&D investments, particularly for high-value therapeutics like those for cancer.
-
How does the patent's disclosure of antibody-drug conjugates (ADCs) affect competitors?
If EP3086783 includes robust claims covering antibody-drug conjugates, particularly those using the defined antibody frameworks linked to specific payloads, competitors developing ADCs targeting CD20 or CD38 using similar antibody components or conjugation strategies may face infringement risks.
-
What is the typical process for validating a European patent in individual member states?
After the European Patent Office grants a patent, the patentee must file a request for validation in each desired member state, usually within a specified time frame (typically 3-6 months from grant publication). This often involves paying national fees and, in some countries, providing translations of the patent claims or the full specification.
Citations
[1] European Patent EP3086783 B1. (2015, December 16). Compositions comprising novel protein for treating cancer. Genentech, Inc.
